Citation Tools
PDFTherapeutics
Randomised controlled trial
Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Telaprevir triple combination therapy, and dual peginterferon α-2a/ribavirin therapy for 24 weeks for those with rapid-early response is not inferior to 48 weeks of therapy for treatment-naïve patients with genotype 1 hepatitis C virus infection